Does the media refer more to AUPH or PCVX?

In the previous week, Vaxcyte had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Vaxcyte and 6 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 1.20 beat Aurinia Pharmaceuticals' score of 0.91 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUPH or APGE?

In the previous week, Apogee Therapeutics had 7 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for Apogee Therapeutics and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Apogee Therapeutics' score of 0.33 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMVT or AUPH?

In the previous week, Immunovant had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Immunovant and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Immunovant's score of 0.58 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUPH or IBRX?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than ImmunityBio. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 5 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat ImmunityBio's score of 0.49 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or RYTM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Rhythm Pharmaceuticals' score of 0.73 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aurinia Pharmaceuticals (AUPH) Competitors

$15.18 -0.27 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$15.15 -0.03 (-0.20%)

As of 06:05 PM Eastern

Compare

AUPH vs. PCVX, APGE, IMVT, IBRX, and RYTM

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? Aurinia Pharmaceuticals's main competitors and comparable companies include Vaxcyte (PCVX), Apogee Therapeutics (APGE), Immunovant (IMVT), ImmunityBio (IBRX), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.14	$287.20M	$2.29	6.63
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 16.38%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 46.11%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Vaxcyte had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Vaxcyte and 6 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 1.20 beat Aurinia Pharmaceuticals' score of 0.91 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Vaxcyte	N/A	-37.56%	-33.62%

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Apogee Therapeutics had 7 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for Apogee Therapeutics and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Apogee Therapeutics' score of 0.33 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Apogee Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Apogee Therapeutics	N/A	-32.16%	-30.91%

Aurinia Pharmaceuticals currently has a consensus target price of $17.67, indicating a potential upside of 16.38%. Apogee Therapeutics has a consensus target price of $124.43, indicating a potential downside of 7.45%. Given Aurinia Pharmaceuticals' higher possible upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Apogee Therapeutics	1 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

Aurinia Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.14	$287.20M	$2.29	6.63
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Aurinia Pharmaceuticals beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Aurinia Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Aurinia Pharmaceuticals	$283.05M	7.14	$287.20M	$2.29	6.63

47.1% of Immunovant shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Immunovant's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Immunovant has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Immunovant presently has a consensus target price of $44.00, suggesting a potential upside of 5.21%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 16.38%. Given Aurinia Pharmaceuticals' higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Immunovant had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Immunovant and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Immunovant's score of 0.58 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Aurinia Pharmaceuticals has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.14	$287.20M	$2.29	6.63
ImmunityBio	$113.29M	71.57	-$351.40M	-$0.97	N/A

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than ImmunityBio. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 5 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat ImmunityBio's score of 0.49 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 16.38%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 85.62%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to ImmunityBio's net margin of -598.55%. Aurinia Pharmaceuticals' return on equity of 26.11% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
ImmunityBio	-598.55%	N/A	-51.65%

Summary

Aurinia Pharmaceuticals beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.91 beat Rhythm Pharmaceuticals' score of 0.73 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 16.38%. Rhythm Pharmaceuticals has a consensus target price of $142.44, suggesting a potential upside of 22.77%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.14	$287.20M	$2.29	6.63
Rhythm Pharmaceuticals	$189.76M	41.90	-$196.54M	-$3.11	N/A

Summary

Aurinia Pharmaceuticals beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.02B	$3.72B	$7.03B	$13.08B
Dividend Yield	N/A	3.76%	2.58%	10.74%
P/E Ratio	6.63	10.40	270.65	25.26
Price / Sales	7.14	1,262.33	641.14	104.62
Price / Cash	15.17	102.94	70.59	50.58
Price / Book	3.29	18.06	13.24	6.24
Net Income	$287.20M	-$13.23M	$3.45B	$347.70M
7 Day Performance	-5.89%	2.29%	2.03%	1.92%
1 Month Performance	-5.30%	0.79%	1.07%	1.05%
1 Year Performance	26.39%	53.96%	67.58%	19.53%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	3.9457 of 5 stars	$15.18 -1.7%	$17.67 +16.4%	+36.5%	$2.02B	$283.05M	6.63	300	Earnings Report
PCVX Vaxcyte	2.1808 of 5 stars	$58.29 +0.4%	$86.00 +47.5%	+98.8%	$8.39B	N/A	N/A	160	Positive News
APGE Apogee Therapeutics	1.0231 of 5 stars	$134.65 -0.1%	$121.25 -9.9%	+266.6%	$8.34B	N/A	N/A	91	Earnings Report Analyst Downgrade
IMVT Immunovant	1.4511 of 5 stars	$39.89 -0.2%	$44.00 +10.3%	+180.1%	$8.25B	N/A	N/A	120	News Coverage Earnings Report
IBRX ImmunityBio	2.4795 of 5 stars	$7.49 -2.0%	$14.20 +89.6%	+213.4%	$8.10B	$113.29M	N/A	590

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, APGE, IMVT, IBRX, and RYTM

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Summary

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, APGE, IMVT, IBRX, and RYTM

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Do insiders and institutionals believe in AUPH or PCVX?

Which has stronger valuation and earnings, AUPH or PCVX?

Do analysts rate AUPH or PCVX?

Does the media refer more to AUPH or PCVX?

Which has more risk and volatility, AUPH or PCVX?

Is AUPH or PCVX more profitable?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Does the media refer more to AUPH or APGE?

Do institutionals & insiders have more ownership in AUPH or APGE?

Is AUPH or APGE more profitable?

Do analysts prefer AUPH or APGE?

Which has more volatility and risk, AUPH or APGE?

Which has better valuation & earnings, AUPH or APGE?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Which has stronger earnings and valuation, IMVT or AUPH?

Do insiders and institutionals hold more shares of IMVT or AUPH?

Is IMVT or AUPH more profitable?

Which has more risk & volatility, IMVT or AUPH?

Do analysts recommend IMVT or AUPH?

Does the media prefer IMVT or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Which has more volatility & risk, AUPH or IBRX?

Which has better valuation and earnings, AUPH or IBRX?

Does the media favor AUPH or IBRX?

Do analysts recommend AUPH or IBRX?

Do institutionals and insiders hold more shares of AUPH or IBRX?

Is AUPH or IBRX more profitable?

Summary

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Is AUPH or RYTM more profitable?

Does the media favor AUPH or RYTM?

Which has more volatility and risk, AUPH or RYTM?

Do analysts recommend AUPH or RYTM?

Do institutionals and insiders hold more shares of AUPH or RYTM?

Which has preferable valuation & earnings, AUPH or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools